Department of Biology, Hong Kong Baptist University, Kowloon, Hong Kong.
J Cell Biochem. 2009 Dec 15;108(6):1356-63. doi: 10.1002/jcb.22366.
Epidermal growth factor receptor (EGFR), a receptor often expressed in nasopharyngeal carcinoma (NPC) cells, is one of the recently identified molecular targets in cancer treatment. In the present study, the effects of combined treatment of Zn-BC-AM PDT with an EGFR inhibitor AG1478 were investigated. Well-differentiated NPC HK-1 cells were subjected to PDT with 1 microM of Zn-BC-AM and were irradiated at a light dose of 1 J/cm(2) in the presence or absence of EGFR inhibitor AG1478. Specific protein kinase inhibitors of downstream EGFR targets were also used in the investigation. EGFR, Akt, and ERK were found constitutively activated in HK-1 cells and the activities could be inhibited by the EGFR inhibitor AG1478. A sub-lethal concentration of AG1478 was found to further enhance the irreversible cell damage induced by Zn-BC-AM PDT in HK-1 cells. Pre-incubation of the cells with specific inhibitors of EGFR (AG1478), PI3k/Akt (LY294002), or MEK/ERK (PD98059) before light irradiation were found to enhance Zn-BC-AM PDT-induced formation of apoptotic cells. The efficacy of Zn-BC-AM PDT can be increased through the inhibition of EGFR/PI3K/Akt and EGFR/MEK/ERK signaling pathways in NPC cells. Combination therapy with Zn-BC-AM PDT and EGFR inhibitors may further be developed for the treatment of advanced NPC.
表皮生长因子受体(EGFR)是一种在鼻咽癌(NPC)细胞中常表达的受体,是癌症治疗中最近确定的分子靶标之一。在本研究中,研究了联合使用 Zn-BC-AM PDT 和 EGFR 抑制剂 AG1478 治疗的效果。将高分化 NPC HK-1 细胞用 1μM 的 Zn-BC-AM 进行 PDT,并在存在或不存在 EGFR 抑制剂 AG1478 的情况下用 1 J/cm²的光剂量照射。还在研究中使用了下游 EGFR 靶标特异性蛋白激酶抑制剂。在 HK-1 细胞中发现 EGFR、Akt 和 ERK 持续激活,并且可以被 EGFR 抑制剂 AG1478 抑制。发现亚致死浓度的 AG1478 进一步增强了 Zn-BC-AM PDT 在 HK-1 细胞中诱导的不可逆细胞损伤。在用光照之前,用 EGFR(AG1478)、PI3k/Akt(LY294002)或 MEK/ERK(PD98059)的特异性抑制剂预孵育细胞,发现可以增强 Zn-BC-AM PDT 诱导的凋亡细胞形成。通过抑制 NPC 细胞中的 EGFR/PI3K/Akt 和 EGFR/MEK/ERK 信号通路,可以提高 Zn-BC-AM PDT 的疗效。Zn-BC-AM PDT 联合 EGFR 抑制剂的联合治疗可能进一步开发用于治疗晚期 NPC。